(Q44477346)

3 December 2017

title

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity (English)

1 reference

3 December 2017

0 references

1 reference

1

George A Bray

1 reference

3 December 2017

3

Samuel Klein

1 reference

3 December 2017

Priscilla Hollander

2

1 reference

3 December 2017

Robert Kushner

4

1 reference

3 December 2017

Brian Levy

5

1 reference

3 December 2017

Martin Fitchet

6

1 reference

3 December 2017

Barbara H Perry

7

1 reference

3 December 2017

publication date

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

11

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

722-733

1 reference

Prevalence and Trends in Obesity Among US Adults, 1999-2000

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Topiramate: a review of preclinical, pharmacokinetic, and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Open-label adjunctive topiramate in the treatment of bipolar disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Step-down multiple tests for comparing treatments with a control in unbalanced one-way layouts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

International trial of long-term dexfenfluramine in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Obesity: a time bomb to be defused

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

The effects of topiramate and sex hormones on energy balance of male and female rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.102

31 March 2020

Identifiers

DOI

10.1038/OBY.2003.102

1 reference

3 December 2017

1 reference